Home » Newsletters » BioWorld Science

BioWorld Science

March 24, 2000

View Archived Issues

Novo Nordisk expands research agreement with DGI BioTechnologies

SkyePharma to develop formulation for Pfizer compound

Morphochem acquires Small Molecule Therapeutics

Corixa and Abgenix form MAb collaboration

Boehringer Ingelheim increases presence in Japanese market

Millennium extends inflammation and autoimmune alliance with Kyowa Hakko

Vasogen cleared to proceed with clinical trial of VAS-981 in leukemia patients

FDA grants orphan drug status to Zadaxin for treatment of liver cancer

Abbott and NPS establish agreement for NPS-1776

Monsanto discloses gastrospecific prodrugs

New ACAT inhibitors in development at Sumitomo

U.K. virtual drug development company adds another product to its pipeline

Small peptides synthesized at Boehringer Ingelheim specifically inhibit HCV NS3 protease

SB reveals more novel anticonvulsants with affinity for novel binding site

Xanthine-based cell adhesion inhibitors particularly useful for periodontitis

Small-molecule GRP receptor antagonists in the pipeline at SB

TNP-470 shows promise in combination with anti-IL-8 antibody or cisplatin for H&N cancer

IL-12 found to have only limited antiviral activity in hepatitis C

Sigma1-receptor confirmed as site of action for antipsychotic MS-377

NO donor FK-409 protects against postischemic myocardial dysfunction in Langendorff hearts

Functional studies confirm potent 5-HT2A-antagonist activity of AT-1015

Three new additions to the Aventis pipeline

Na/Ca2+ exchange inhibitor KB-R7943 evaluated for effects on platelet aggregation

Cephalon expands marketing coverage of Provigil to Latin America and Asia

Neurotrophic and cognition-enhancing effects reported for TEI-3356 this week in Yokohama

CV Therapeutics commences second phase II clinical trial for CVT-510

The novel antiarrhythmic agent NIP-142 may act by blocking open Kv1.5 potassium channels

Matrix commences two new clinical trials with FMdC